The DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Treatment Outcomes for Serious Infections Caused by Methicillin‐Resistant Staphylococcus aureus with Reduced Vancomycin Susceptibility
Abstract
Although infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility (SA-RVS) have been reported from a number of countries, including Australia, the optimal therapy is unknown. We reviewed the clinical features, therapy, and outcome of 25 patients with serious infections due to SA-RVS in Australia and New Zealand. Eight patients had endocarditis, 9 had bacteremia associated with deep-seated infection, 6 had osteomyelitis or septic arthritis, and 2 had empyema. All patients had received vancomycin before the isolation of SA-RVS, and glycopeptide treatment had failed for 19 patients (76%). Twenty-one patients subsequently received active treatment, which was effective for 16 patients (76%). Eighteen patients received linezolid, which was effective in 14 (78%), including 4 patients with endocarditis. Twelve patients received a combination of rifampicin and fusidic acid. Surgical intervention was required for 15 patients (60%). Antibiotic therapy, especially linezolid with or without rifampicin and fusidic acid, in conjunction with surgical debulking is effective therapy for the majority of patients with serious infections (including endocarditis) caused by SA-RVS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically
Ferraro, M. J. (2000) · Cited by 16,875
Manual of Clinical Microbiology.
(1980) · Annals of Internal Medicine · doi:10.7326/0003-4819-93-6-939_2 · Cited by 14,411
Proposed Modifications to the Duke Criteria for the Diagnosis of Infective Endocarditis
Li, J. S., Sexton, D. J., Mick, N., Nettles, R., Fowler, V. G., Ryan, T., Bashore, T., & Corey, G. R. (2000) · Clinical Infectious Diseases · doi:10.1086/313753 · Cited by 4,027
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility
Hiramatsu, K. (1997) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/40.1.135 · Cited by 1,984
Hiramatsu, K., Aritaka, N., Hanaki, H., Kawasaki, S., Hosoda, Y., Hori, S., Fukuchi, Y., & Kobayashi, I. (1997) · The Lancet · doi:10.1016/s0140-6736(97)07324-8 · Cited by 1,333
Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance
Hiramatsu, K. (2001) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(01)00091-3 · Cited by 759
Murchan, S., Kaufmann, M. E., Deplano, A., de Ryck, R., Struelens, M., Zinn, C. E., Fussing, V., Salmenlinna, S., Vuopio-Varkila, J., El Solh, N., et al. (2003) · Journal of Clinical Microbiology · doi:10.1128/jcm.41.4.1574-1585.2003 · Cited by 637
Wootton, M. (2001) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/47.4.399 · Cited by 414
Increasing Resistance to Vancomycin and Other Glycopeptides in Staphylococcus aureus
Tenover, F. C., Biddle, J. W., & Lancaster, M. V. (2001) · Emerging Infectious Diseases · doi:10.3201/eid0702.010237 · Cited by 391
Charles, P. G. P., Ward, P. B., Johnson, P. D. R., Howden, B. P., & Grayson, M. L. (2004) · Clinical Infectious Diseases · doi:10.1086/381093 · Cited by 384
Self-citation
Cited by
Liu, C., Bayer, A., Cosgrove, S. E., Daum, R. S., Fridkin, S. K., Gorwitz, R. J., Kaplan, S. L., Karchmer, A. W., Levine, D. P., Murray, B. E., et al. (2011) · Clinical Infectious Diseases · doi:10.1093/cid/ciq146 · Cited by 4,191
Rybak, M., Lomaestro, B., Rotschafer, J. C., Moellering, R., Craig, W., Billeter, M., Dalovisio, J. R., & Levine, D. P. (2009) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp080434 · Cited by 1,795
Daptomycin versus Standard Therapy for Bacteremia and Endocarditis Caused by Staphylococcus aureus
Fowler, V. G., Boucher, H. W., Corey, G. R., Abrutyn, E., Karchmer, A. W., Rupp, M. E., Levine, D. P., Chambers, H. F., Tally, F. P., Vigliani, G. A., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053783 · Cited by 1,459
Emergence and resurgence of meticillin-resistant Staphylococcus aureus as a public-health threat
Grundmann, H., Aires-de-Sousa, M., Boyce, J., & Tiemersma, E. (2006) · The Lancet · doi:10.1016/s0140-6736(06)68853-3 · Cited by 1,101
Howden, B. P., Davies, J. K., Johnson, P. D. R., Stinear, T. P., & Grayson, M. L. (2010) · Clinical Microbiology Reviews · doi:10.1128/cmr.00042-09 · Cited by 962
Self-citationPredictors of Mortality in Staphylococcus aureus Bacteremia
van Hal, S. J., Jensen, S. O., Vaska, V. L., Espedido, B. A., Paterson, D. L., & Gosbell, I. B. (2012) · Clinical Microbiology Reviews · doi:10.1128/cmr.05022-11 · Cited by 932
General Principles of Antimicrobial Therapy
Leekha, S., Terrell, C. L., & Edson, R. S. (2011) · Mayo Clinic Proceedings · doi:10.4065/mcp.2010.0639 · Cited by 878
Levine, D. P. (2006) · Clinical Infectious Diseases · doi:10.1086/491709 · Cited by 838
The Pharmacokinetic and Pharmacodynamic Properties of Vancomycin
Rybak, M. J. (2006) · Clinical Infectious Diseases · doi:10.1086/491712 · Cited by 774
Soriano, A., Marco, F., Martinez, J. A., Pisos, E., Almela, M., Dimova, V. P., Alamo, D., Ortega, M., Lopez, J., & Mensa, J. (2008) · Clinical Infectious Diseases · doi:10.1086/524667 · Cited by 767
Ji, H., Li, X., & Zhang, H. (2009) · EMBO reports · doi:10.1038/embor.2009.12 · Cited by 636
Mwangi, M. M., Wu, S. W., Zhou, Y., Sieradzki, K., de Lencastre, H., Richardson, P., Bruce, D., Rubin, E., Myers, E., Siggia, E. D., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0609839104 · Cited by 538
Vancomycin resistance in Staphylococcus aureus
Appelbaum, P. C., & Bozdogan, B. (2004) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2004.03.004 · Cited by 485
Copper as an antimicrobial agent: recent advances
Salah, I., Parkin, I. P., & Allan, E. (2021) · RSC Advances · doi:10.1039/d1ra02149d · Cited by 453
Tenover, F. C., & Moellering, R. C. (2007) · Clinical Infectious Diseases · doi:10.1086/513203 · Cited by 452
Bactericidal agents in the treatment of MRSA infections--the potential role of daptomycin
French, G. L. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl393 · Cited by 441
(2020) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000003668 · Cited by 423
Steinkraus, G., White, R., & Friedrich, L. (2007) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkm258 · Cited by 420
The emergence of vancomycin-intermediate and vancomycin-resistant Staphylococcus aureus
Appelbaum, P. C. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01344.x · Cited by 376
Howden, B. P., McEvoy, C. R. E., Allen, D. L., Chua, K., Gao, W., Harrison, P. F., Bell, J., Coombs, G., Bennett-Wood, V., Porter, J. L., et al. (2011) · PLoS Pathogens · doi:10.1371/journal.ppat.1002359 · Cited by 370
Self-citationWang, G., Hindler, J. F., Ward, K. W., & Bruckner, D. A. (2006) · Journal of Clinical Microbiology · doi:10.1128/jcm.01388-06 · Cited by 358
Mechanisms of Antibiotic Resistance in Staphylococcus Aureus
Pantosti, A., Sanchini, A., & Monaco, M. (2007) · Future Microbiology · doi:10.2217/17460913.2.3.323 · Cited by 348
The importance of the development of antibiotic resistance in Staphylococcus aureus
Schito, G. C. (2006) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01343.x · Cited by 302
Increasing Antibiotic Resistance among Methicillin‐Resistant Staphylococcus aureus Strains
Sakoulas, G., & Moellering, Jr. (2008) · Clinical Infectious Diseases · doi:10.1086/533592 · Cited by 274
Sánchez García, M. (2010) · JAMA · doi:10.1001/jama.2010.757 · Cited by 270
Clinical management of Staphylococcus aureus bacteraemia
Thwaites, G. E., Edgeworth, J. D., Gkrania-Klotsas, E., Kirby, A., Tilley, R., Török, M. E., Walker, S., Wertheim, H. F., Wilson, P., & Llewelyn, M. J. (2011) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(10)70285-1 · Cited by 261
Jones, R. N. (2006) · Clinical Infectious Diseases · doi:10.1086/491710 · Cited by 254
Moellering, R. C. (2012) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkr437 · Cited by 236
Falagas, M. E. (2006) · Journal of Antimicrobial Chemotherapy · doi:10.1093/jac/dkl219 · Cited by 167
Riedel, D. J., Weekes, E., & Forrest, G. N. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00300-08 · Cited by 136
Bae, I., Federspiel, J. J., Miró, J. M., Woods, C. W., Park, L., Rybak, M. J., Rude, T. H., Bradley, S., Bukovski, S., de la Maria, C. G., et al. (2009) · The Journal of Infectious Diseases · doi:10.1086/606027 · Cited by 122
Self-citationJang, H., Kim, S., Kim, K. H., Kim, C. J., Lee, S., Song, K., Jeon, J. H., Park, W. B., Kim, H. B., Park, S., et al. (2009) · Clinical Infectious Diseases · doi:10.1086/600295 · Cited by 113
Rose, W. E., Leonard, S. N., Sakoulas, G., Kaatz, G. W., Zervos, M. J., Sheth, A., Carpenter, C. F., & Rybak, M. J. (2008) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00869-07 · Cited by 81
Linezolid therapy for infective endocarditis
Muñoz, P., Rodríguez-Creixéms, M., Moreno, M., Marín, M., Ramallo, V., Bouza, E., & GAME Study Group (2007) · Clinical Microbiology and Infection · doi:10.1111/j.1469-0691.2006.01585.x · Cited by 68
Rose, W. E., Leonard, S. N., Rossi, K. L., Kaatz, G. W., & Rybak, M. J. (2009) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01009-08 · Cited by 37
Metadata
- Authors
- Howden, B. P., Ward, P. B., Charles, P. G. P., Korman, T. M., Fuller, A., Cros, P. D., Grabsch, E. A., Roberts, S. A., Robson, J., Read, K., Bak, N., Hurley, J., Johnson, P. D. R., Morris, A. J., Mayall, B. C., & Lindsay Grayson, M.
- Venue
- Clinical Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2004-02-15
- Volume
- 38
- Issue
- 4
- Pages
- 521-528
- ISSN
- 1058-4838 (ISSN-L)
- 1537-6591
- OpenAlex
- W2160244430
- Cited by
- 484
- References
- 21
- FWCI
- 22.45
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.